Susan Bobulsky Sells 5,000 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 5,000 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $19.00, for a total transaction of $95,000.00. Following the completion of the transaction, the insider directly owned 411,775 shares of the company’s stock, valued at $7,823,725. This represents a 1.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $18.00, for a total value of $198,000.00.

Adaptive Biotechnologies Stock Down 1.4%

Shares of Adaptive Biotechnologies stock opened at $17.22 on Wednesday. The company has a market capitalization of $2.76 billion, a price-to-earnings ratio of -52.18 and a beta of 2.15. The stock’s 50-day simple moving average is $14.67 and its 200-day simple moving average is $15.61. Adaptive Biotechnologies Corporation has a 52 week low of $9.96 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter last year, the company earned ($0.20) EPS. The firm’s quarterly revenue was up 35.1% on a year-over-year basis. On average, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Morgan Stanley reduced their target price on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. JPMorgan Chase & Co. dropped their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $19.57.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ADPT. California State Teachers Retirement System boosted its holdings in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after acquiring an additional 933 shares during the period. PNC Financial Services Group Inc. increased its stake in Adaptive Biotechnologies by 6.8% in the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock worth $205,000 after purchasing an additional 941 shares during the period. Captrust Financial Advisors increased its stake in Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after purchasing an additional 1,119 shares during the period. Assetmark Inc. lifted its position in shares of Adaptive Biotechnologies by 46.4% during the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after purchasing an additional 1,401 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Adaptive Biotechnologies by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after purchasing an additional 1,532 shares during the period. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.